Mycobiology

The Korean Society of Mycology (한국균학회)
권호 표지
DOI QR코드

DOI QR Code

In Vitro Antifungal Activities of Amphotericin B, Fluconazole, Itraconazole, Terbinafine, Caspofungin, Voriconazole, and Posaconazole against 30 Clinical Isolates of Cryptococcus neoformans var. neoformancs

  • Lee, Young-Ki (Seoul Government Research Institute of Public Health & Environment) ;
  • Fothergill, Annette W. (Fungus Testing Laboratory, Department of Pathology, The University of Texas Health Science Center at San Antonio)
  • Published : 2003.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Aantifungal agents were tested against 30 clinical isolates of Cryptococcus neoformans var. neoformans using the NCCLS method(M27-A2). Posaconazole, itraconazole and amphotericin B had lower MIC than the remaining four antifungal agents. The MIC result for posaconazole was over 220-fold lower active than fluconazole. Fluconazole MICs for most isolates fell within the dose-dependant range. The overall MIC ranges and $MIC_{50}s$ were amphotericin B(0.03-0.25; 0.25), fluconazole(0.5-64; 16), itraconazole(0.015-1; 0.125), terbinafine(0.06->2; 1), caspofungin(8-32; 32), voriconazole(0.015-0.5; 0.25), and posaconazole(0.015-0.25; 0.06 ${\mu}g/ml$), respectively. In conclusion, the $MIC_{50}s$ of these drugs did not exhibit any sign of an upward shift with the exception of fluconazole and tendency cross-resistance between the seven drugs was not observed. We conclude that in vitro resistance to antifungal agents has not significantly changed despite the recent wide-spread use of triazoles for long-term treatment of Cryptococcal meningitis.

Keywords

References

  1. Aleves, S. H., Oliveira, L. T., Jane, M. C., Lubeck, I., Agnes, K. and Vainsteni, M. H. 2001. In Vitro Susceptibility to Antifungal Agents of Clinical and Environmental Cryptococcus neo-formans Isolated in southern of Brazil. Rev. Inst. Med. Trop. S. Paulo 43(5): 267-270 https://doi.org/10.1590/S0036-46652001000500006
  2. Ana, E. I. 1998. In vitro Activity of the New Triazole Voriconazole (UK-109,496) against Opportunistic Filamentous and Dimorphic Fungi and Common and Emerging Yeast Pathogens. J. Clin. Microbial. 36: 198-202
  3. Brandt, M. E., Michael, A. P., Rana, A. H., Richard, J. H., Peter, G. P, Arthur, L. R., David, R. and Warnock, D. W 2001. Trends in Antifungal Drug Susceptibility of Cryptococcus neo-formans Isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrobial agents and chemotherapy 45: 3065-3069 https://doi.org/10.1128/AAC.45.11.3065-3069.2001
  4. Davey, K G., Johnson, E. M., Holmes, A. D., Szekely, A. and Warnock, D. W. 1998. In Vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole. Journal of Antimicrobial Chemotherapy 42: 217-220 https://doi.org/10.1093/jac/42.2.217
  5. Davey, K G., Szekely, A. E., Johnson, M. and Warnock, D. W. 1998. Comparison of a new commercial colorimetric microdilution method with a standard method for in vitro susceptibility testing of Candida spp. and Cryptococcus neoformans. Journal of Antimicrobial Chemotherapy 42: 439-444
  6. Franzot, S. P. and Hamdan, J. S. 1996. In Vitro Susceptibilities of Clinical and Environmental Isolates of Cryptococcus neoformans to Five Antifungal Drugs. Antimicrobial. Agents and Chemotherapy 40: 822-824
  7. Kirkpatrick, W R., Mcatee, R. K., Revankar, S. G. Fothergill, A. W, Mccarthy, D. I., Rinaldi, M. G. and Patterson, T. F. 1998. Comparative Evaluation of National Committee for Clinical Laboratory Standards Broth Macrodilution and Agar Dilution Screenin Methods for Testing Fluconazole Susceptibility of Cryptococcus neoformans. J. Clin. Microbiol. 36: 1330-1332
  8. Mondon, P. R., Amalfitano, P. G., Luzzati, R., Concia, E., Polacheck, I. and Kwon-Chung, K. J. 1999. Heteroresistance to Fluconazole and Voriconazole in Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy 43: 1856-1861
  9. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Villanova, Pa
  10. Pappas, P. G., John, R. P., Gretchen, A. C, Robert, A. L., Feorge, A. P., Daniel, J. L., Harold, H. A., Carol, K., David, W H., Michael, S., Richard, J. H., Melissa, S. H., Robert, M. Wand William, E. D. 2001. Cryptococcosis in Human Immunodeficiency Virus-Negative Patients in the Era of Effective Azole Therapy. HIV/AIDS 33: 690-699
  11. Perea, S. and Patterson, T. F. 2002. Antifungal Resistance in Pathogenic Fungi. Antimicrobial Resistance 35: 1073-1080
  12. Perfect, J. R., Cox, G. M., Dodge, R. K. and Schell, W. A. 1996. In Vitro and In Vivo Effectives of the Azole SCH56592 against Cryptococcus neoformans. Antimicrobial. Agents and Chemotherapy 40: 1910-1913
  13. Pfaller, M. A., Bale, M., Buschelman, B., Lancaster, M., Ana, E. I., Rex, J. H., Rinald, M. G., Cooper, C. R. and Mcginnis, M. R. 1995. Quality Control Guidelines for National Committee for Clinical Laboratory Standards Recommended Broth Macrodilution Testing of Amphotericin B, Fluconazole, and Flucytosine. J. Clin. Microbiol. 33(5): 1104-1107
  14. Pfaller, M. A., Messer, S. A., Hollis, R. J. and Jones, R. N. 2001. In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy 45: 2862-2864 https://doi.org/10.1128/AAC.45.10.2862-2864.2001
  15. Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V; Ana, E. I., Ghannoum, M. A. Gosey, L. L., Odds, F. C, Rinaldi, M. G., Sheehan, D. J. and Warnock, D. W 2001. FOCUS. Antifungal Susceptibility Testing: Practical Aspects and Current Challenges. Clinical Microbiology Reviews 14: 643-658
  16. Roling, E. E., Klepser, M. E., wasson, A., Lewis, R. E. Ernst, E. J. and Pfaller, M. A. 2002. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp, and Crytococcus neoformans via timekill methods. Mycology. Diagnostic Microbiology and Infectious Disease 43: 13-17 https://doi.org/10.1016/S0732-8893(02)00361-9
  17. Ryder, N. S., Wagner, S. and Leitner, I. 1998. In Vitro Activities of Terbinafine agaist Cutaneous Isolates of Candida albicans and Other Pathogenic Yeasts. Antimicrobial. Agents and Chemotherapy 42: 1057-1061
  18. Saag, M. S., Richard, J. G., Robert, A. L., Peter, P., John, R. P., William, P., Jack, D. S. and William, E. D. 2000. Practice Guidelines for the management of Cryptococcal Disease. Clinical Infectious Diseases 30: 710-718 https://doi.org/10.1086/313757
  19. Sheehan, D. J., Hitchcock, C. A. and Sibley, C. M. 1999. Current and Emerging Azole Antifungal Agents. Clinical Microbiology Reviews 12: 40-79
  20. Yidliran, S. T., Fotrergill, A. W., Sutton, D. A. and Rinaldi, M. G. 2002. In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year Period against fluconazole, voriconazole and posaconazole (SCH56592). Mycoses. 45: 378-383 https://doi.org/10.1046/j.1439-0507.2002.00765.x
  21. Yildiran, S. T., Saracli, M. A., Fothergill, A. Wand Rinaldi, M. G. 2000. In Vitro Susceptibility of Environmental Cryptococcus neoformans variety neoformans Isolates from Turkey to Six Antifungal Agents, Including SCH56592 and Voriconazole. Eur. J. Clin. Microbilo Infect. Dis. 19: 317-319 https://doi.org/10.1007/s100960050484
  22. White, T. C, Marr, K. A. and Bowden, R. A. 1998. Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance. Clinical Microbilogy Reviews 11: 382-402

Cited by

  1. -1,2,4-triazol-4-yl]propanoic Acid Derivatives in Aqueous Media vol.2013, pp.1537-744X, 2013, https://doi.org/10.1155/2013/716389
  2. -1,2,4-triazole derivatives: a patent review (2008 – 2011) vol.23, pp.3, 2013, https://doi.org/10.1517/13543776.2013.749862